Therapeutic Effectiveness of a Generic versus Original
Meropenem in Serious Infections
Somboon Tansuphasawadikul MD*,
Songchai Simaroj MD**, Somchai Chantarothorn MD***,
Nontakan Nuntachit MD****, Kamonwan Jutivorakool MD*****,
Warangkana Munsakul MD******, Kanittha Yomtem MD*******,
Thitirat Tangkosakul MD********, Suppaleark Wannasunthornchai MD*********
* Buddhachinnaraj Hospital, Phitsanulok, Thailand
** Police General Hospital, Bangkok, Thailand
*** Somdej Phrapinklao Hospital, Bangkok, Thailand
**** Chiang Mai University, Chiang Mai, Thailand
***** Chulalongkorn University, Bangkok, Thailand
****** BMA Medical College and Vajira Hospital, Bangkok, Thailand
******* Narathiwas Hospital, Narathiwas, Thailand
******** Lerdsin Hospital, Bangkok, Thailand,
********* Udon Thani Hospital, Udon Thani, Thailand
Background: Meropenem plays a significant role in the current antimicrobial treatment of serious infections. Recently,
generic meropenems have become widely available in Thailand.
Objective: Compare the effectiveness and safety of a generic meropenem (Mapenem®) with the original meropenem (Meronem®)
in clinical practice.
Material and Method: A retrospective cohort study was conducted in hospitalized patients with serious infections that had
been treated with either the generic or the original meropenem in nine secondary- and tertiary-care hospitals nationwide. The
treatment outcomes at days 3, 7, and 14 after the use of meropenem between the two groups were compared.
Results: Three hundred ninety seven patients with a mean (SD) age of 66.4 + 16.9 years were included. There were 228
(57.4%) males and 169 (42.6%) females. Two hundred and seven (52.1%) and 190 (47.9%) cases fell into the generic and
original groups respectively. There were no significant differences regarding age, gender, history of underlying disease, body
weight, and ward of admission between the two groups. The majority of patients had presented with the respiratory tract
(48.6%) and blood stream infections (29.5%). The three most common causative bacteria were Pseudomonas aeruginosa,
Acinetobacter baumannii, and extended-spectrum beta-lactamase (ESBL) producing Escherichia coli. The distribution of the
sites of infection, causative microorganisms, the dosage of meropenem, and duration of treatment were similar between the
two groups. The distribution of patients with complete resolution, improvement, stable, worse, died from infection, and died
from other causes were similar between the two groups at day 3, 7, and 14 of meropenem use (p > 0.05). The drugs were welltolerated, and less than 2% of patients in both groups discontinued meropenem due to the adverse drug effects.
Conclusion: The generic meropenem has a similar effectiveness in the treatment of serious bacterial infections when
compared with original meropenem. Both formulations are well tolerated among patients with substantial comorbidities.
Adverse drug effects that lead to drug discontinuation are uncommon.
Keywords: Meropenem, Effectiveness, Carbapenems, Generic, Original
J Med Assoc Thai 2011; 94 (2): 172-8
Full text. e-Journal: http://www.mat.or.th/journal
In the era of gram-negative bacterial resistance,
carbapenems play a significant role since they provide
better gram-negative coverage than other beta-lactams
Correspondence to:
Nantajit N, Division of Infectious Disease, Department of
Internal Medicine, Faculty of Medicine, Chiang Mai University,
Chiang Mai 50200, Thailand.
Phone: 053-945-482, Fax: 053-945-481
E-mail: nnuntach@mail.med.cmu.ac.th
172
and are stable against extended-spectrum betalactamases (ESBL) and AmpC beta-lactamases where
third generation cephalosporins are not effective(1-6).
Meropenem is a carbapenem that is more
active against Gram-negative bacteria. A recent study
showed that a generic meropenem is pharmaceutical
equivalent and fulfills the requirements of the
US Pharmacopoeia (XXVIII) in relation to their
activities (7). This generic meropenem has been
J Med Assoc Thai Vol. 94 No. 2 2011
approved by the Thai Food and Drug Administration
after it demonstrated indifferent bioequivalence and
antibacterial activity(8), as well as safety, and tolerability.
In the present study, the authors aimed to compare the
effectiveness and safety of the generic with original
meropenem in the real-life clinical practice setting after
it has been available in many hospitals in Thailand for
more than a year.
Material and Method
A retrospective cohort study was conducted
in hospitalized patients who had been treated with
either the generic or the original meropenem in nine
secondary- and tertiary-care hospitals nationwide.
These included King Chulalongkorn Memorial
Hospital, Lerdsin Hospital, Police General Hospital,
Somdej Phrapinklao Hospital and Vajira Hospital at
Bangkok, Buddhachinnaraj Hospital at Phitsanulok,
Chiang Mai University Hospital at Chiang Mai,
Narathiwas Hospital at Narathiwas, and Udon Thani
Hospital at Udon Thani, Thailand. The present study
was conducted between April 1, 2007 and February 28,
2010.
Inclusion criteria were hospitalized adults (>
15 years old) with serious bacterial infections, such as
lower respiratory tract infection, necrotizing skin/soft
tissue infection, nosocomial or health-care associated
intra-abdominal infection and sepsis. Etiologic agents
of these infections were mostly multi-drug resistant
Gram-negative bacilli or ESBL-producing Enterobacteriaceae, with or without anaerobic bacteria.
The patients received either a generic meropenem
(Mapenem®) or an original meropenem (Meronem®).
Baseline data were collected from the medical
records. They including demographic data, underlying
diseases, date and duration of hospitalization, site of
infections, clinical specimens for microbiological
cultures, antimicrobial agents used prior and during
the hospitalization, duration of meropenem used,
laboratory results, adverse drug effects, and outcomes
of treatment at days 3, 7, and 14 after the use of the
meropenem. The present study was approved by the
institutional review board and/or ethical clearance
committee of the Ministry of Public Health.
Data analysis
Continuous data with normal distribution
were shown as mean and standard deviation (SD) and
those with non-normal distribution as median and
interquartile range (IQR). Categorical data were shown
as frequency and percentage. Study patients were
J Med Assoc Thai Vol. 94 No. 2 2011
categorized into generic or original meropenem
groups. Continuous data were compared between the
two groups using independent t-test or the MannWhitney U test. Chi-square test or Fisher’s exact test
was used for categorical data analysis where
appropriate. Clinical outcomes at days 3, 7 and 14 after
meropenem use were compared. All analysis was
performed using the SPSS version 14.0. A p-value of
< 0.05 was considered statistical significance.
Results
Three hundred ninety seven patients from
nine hospitals were included in the present study
(Buddhachinnaraj Hospital 80 patients, Police General
Hospital 80 patients, Somdej Phrapinklao Hospital 80
patients, Chiang Mai University Hospital 78 patients,
King Chulalongkorn Memorial Hospital 21 patients,
Vajira Hospital 20 patients, Narathiwas Hospital 20
patients, Lerdsin Hospital 11 patients, and Udon Thani
Hospital 7 patients). The age (mean + SD) was 66.4 +
16.9 years. Two hundred and twenty-eight (57.4%)
patients were male and 169 (42.6%) were females. Of
397 patients, 272 (68.5%) were hospitalized in the
intensive care units. Two hundred and seven (52.1%)
cases were in the generic meropenem group and
190 (47.9%) patients were in the original meropenem
group. Table 1 shows the comparison of baseline
characteristics between the two groups. There were
no significant differences of age, gender, history
of underlying disease, body weight, and ward of
admission.
The sites of infection in the majority of
patients were the respiratory tract (48.6%) and blood
stream (29.5%) infections. The rest were urinary tract,
skin and soft tissue, intra-abdominal cavity, central
nervous system and bone and joints. The three most
common causative microorganisms were Pseudomonas
aeruginosa, Acinetobacter baumannii, and ESBLproducing Escherichia coli. The distribution of the
sites of infections and causative microorganisms are
shown in Table 2. There were no statistical differences
of the distribution of the sites of infection and causative
microorganisms between the two groups, except for
ESBL-producing E. coli, which was significantly
higher in the generic meropenem group. The baseline
laboratory results including complete blood counts,
liver function tests, blood urea nitrogen and serum
creatinine were similar between the two groups (data
not shown).
More than eighty percent of patients in both
groups had previously used other antimicrobial agents
173
Table 1. Baseline characteristics of 397 study patients
Variables
Age, years, mean (SD)
Male gender, number (%)
History of underlying disease, number (%)
Hypertension
Diabetes mellitus
Chronic kidney disease
Ischemic heart disease
Chronic lung disease
Chronic liver disease
Cancer
Body weight, kg, mean (SD)
Ward of admission
General ward
Intensive care unit
Generic meropenem group
(n = 207)
Original meropenem group
(n = 190)
p-value
65.7 (16.9)
124 (59.9)
191 (92.3)
90 (43.5)
59 (28.5)
41 (19.8)
32 (15.5)
18 (8.7)
9 (4.3)
27 (13.0)
51.8 (10.3)
67.2 (17.0)
104 (54.7)
174 (91.6)
84 (44.2)
64 (33.7)
37 (19.5)
23 (12.1)
27 (14.2)
17 (8.9)
23 (12.1)
54.3 (10.0)
0.399
0,309
0.939
0.919
0.277
0.954
0.384
0.084
0.070
0.880
0.151
0.536
144 (69.6)
63 (30.4)
128 (67.4)
62 (32.6)
Table 2. Clinical features of the 397 study patients by sites of infection and micro-organism
Variables
Generic meropenem group
(n = 207)
Original meropenem group
(n = 190)
95 (45.9)
59 (28.5)
56 (27.1)
28 (13.5)
17 (8.2)
2 (1.0)
1 (0.5)
51 (24.6)
98 (51.6)
58 (30.5)
42 (22.1)
16 (8.4)
14 (7.4)
4 (2.1)
1 (0.5)
41 (21.6)
0.924
46 (22.2)
48 (23.2)
5 (2.4)
44 (21.3)
5 (2.4)
29 (14.0)
10 (4.8)
5 (2.4)
31 (15.0)
44 (23.2)
37 (19.5)
8 (4.2)
22 (11.6)
6 (3.2)
24 (12.6)
3 (3.9)
4 (1.2)
26 (13.7)
0.487
0.319
0.401
0.010
0.764
0.768
0.887
0.653
0.258
Site of infections*, number (%)
Respiratory tract
Blood stream
Urinary tract
Skin and soft tissue
Intra-abdominal
Central nervous system
Bone and joints
Multiple sites of infection, number (%)
Causative microorganisms**, number (%)
P. aeruginosa
A. baumannii
E. coli
ESBL-p E. coli
K. pneumoniae
ESBL-p K. pneumoniae
Enterobacter cloacae
Enterococcus sp.
Others
p-value
0.196
* Some patients had more than one site of infection
** Some patients had more than one microorganism
ESBL-p = extended spectrum beta-lactamase producing
for other episodes of infection prior to the use of
meropenem in the same hospitalization (84.5% vs.
81.1%, p = 0.424). Ceftriaxone and ceftazidime were
such antimicrobials frequently used in both groups.
There was no difference of the median durations of
174
prior antimicrobial therapy between the two groups
(6 vs. 5 days, p = 0.617).
The median and IQR of daily dose of
meropenem were 2.0 (1.5-3.0) grams in both groups.
The median duration of meropenem use was not
J Med Assoc Thai Vol. 94 No. 2 2011
different between the two groups (9 vs. 10 days, p =
0.285). In addition to meropenem, other antimicrobial
agents were concomitantly used in 44.0% of generic
meropenem group and 54.7% of original meropenem
group (p = 0.035). The common concomitant antimicrobial agents used were cefoperazole/sulbactam,
ciprofloxacin, colistin, vancomycin and metronidazole.
Table 3 shows the comparison of clinical outcomes of
397 study patients. The distribution of patients with
complete resolution, improved, stable, worse, died from
infection, and died from other causes between the two
groups were similar at days 3, 7 and 14.
The rate of total adverse drug effects was
slightly higher in the original meropenem group but
the difference was not significant. Common adverse
drug effects in both groups were rashes and acute renal
failure (Table 4). Less than 2% of patients in both
groups discontinued meropenem due to its adverse
drug effects.
Discussion
The results from the current study
demonstrated the similarity of effectiveness of the
generic and original meropenem therapy in both fixedtime points at 3, 7, and 14 days of meropenem use. In
addition, patients in both groups tolerated meropenem
well, with minimal adverse drug effects that lead to
drug discontinuation. Of note, patients in the present
study were very old, had a high proportion of underlying
diseases, and the majority of them needed to be
hospitalized in intensive care units.
Respiratory tract infection was the major
entity of clinical presentations in the present study.
Previous clinical trials had shown that meropenem is
effective and well tolerated by patients with hospitalacquired pneumonia, including a subgroup of patients
with ventilator-associated pneumonia(9-11). In addition,
meropenem had also proved to effectively useful in
patients with bloodstream infections and infections of
urinary tract, skin and soft tissue, intra-abdominal,
central nervous system, and bone and joints(4-6). In
the present study, the three most common causative
microorganisms were Pseudomonas aeruginosa,
Acinetobacter baumannii, and ESBL producing
Escherichia coli. Meropenem has a good activity
against P. aeruginosa, and ESBL-producing E. coli(4-6,12).
Table 3. Clinical outcomes of the 397 study patients
Outcomes
Clinical outcomes at day 3, number (%)
Complete resolution
Improved
Stable
Worse
Died from infection
Died from other causes
Missing data
Clinical outcomes at day 7, number (%)
Complete resolution
Improved
Stable
Worse
Died from infection
Died from other causes
Missing data
Clinical outcomes at day 14, number (%)
Complete resolution
Improved
Stable
Worse
Died from infection
Died from other causes
Missing data
J Med Assoc Thai Vol. 94 No. 2 2011
Generic meropenem group
(n = 207)
Original meropenem group
(n = 190)
6 (2.9)
101 (48.8)
92 (44.3)
2 (1.0)
2 (1.0)
2 (1.0)
2 (1.0)
4 (2.1)
78 (41.1)
83 (43.7)
8 (4.2)
10 (5.3)
2 (1.1)
5 (2.5)
42 (20.3)
96 (46.4)
24 (11.6)
6 (2.9)
8 (3.9)
8 (3.9)
23 (11.0)
24 (12.6)
84 (44.2)
29 (15.3)
11 (5.8)
15 (7.9)
8 (4.2)
19 (10.0)
64 (30.9)
87 (42.0)
7 (3.4)
5 (2.4)
12 (5.8)
10 (4.8)
24 (11.7)
44 (23.2)
78 (41.1)
11 (5.8)
5 (2.6)
21 (11.1)
13 (6.8)
18 (9.4)
p-value
0.059
0.284
0.089
175
Table 4. Adverse drug reaction (ADR) and discontinuation of meropenem in 397 study patients
Outcomes
Generic meropenem group Original meropenem group p-value
(n = 207)
(n = 190)
Total ADR, number (%)
Rashes
Pancytopenia
Thrombocytopenia
Acute renal failure
Seizure
Discontinuation of meropenem due to ADR, number (%)
Rashes
Acute renal failure
Pancytopenia
6 (2.9)
4 (1.9)
0
0
2 (1.0)
0
4 (1.9)
3 (1.4)
1 (0.5)
0
However, activity of meropenem against A. baumannii
in Thailand may be compromised(13,14). Recent studies
reported that addition of cefoperazone/sulbactam to
meropenem might be useful for infections caused by
MDR A. baumannii(14,15). However, the addition of other
antimicrobials during meropenem use, could contribute
to successful therapy or adverse effect as well.
The overall mortality rate at 14 days of
meropenem use was 14.1%, which is lower than the
previous open-label study(16). However, the mortality
rate could be underestimated due to missing data in
some patients. Thus, the nature of retrospective study
is a limitation of the present study. Other limitations
include the limited data of in vitro susceptibility of
causative bacteria, and APACHE score. Nevertheless,
this multicenter cohort study provides an important
clinical data in real-life practice and to the authors’ best
knowledge, is the first comparative study of generic
and original meropenem.
In conclusion, therapy of the generic
meropenem has similar effectiveness in the treatment
of serious infections when compared to the original
meropenem. Both formulations are well tolerated
among patients with substantial comorbidities. Adverse
drug effects that lead to drug discontinuation are
uncommon.
Safety Network, 2006-2008. Infect Control Hosp
Epidemiol 2010; 31: 528-31.
Werarak P, Kiratisin P, Thamlikitkul V. Hospitalacquired pneumonia and ventilator-associated
pneumonia in adults at Siriraj Hospital: etiology,
clinical outcomes, and impact of antimicrobial
resistance. J Med Assoc Thai 2010; 93 (Suppl 1):
S126-38.
Sirichot S, Diraphat P, Utrarachkij F, Tribuddharat
C, Siripanichgon K. Dissemination of class I
integron in Acinetobacter baumliannii isolated
from ventilator-associated pneumonia patients and
their environment. Southeast Asian J Trop Med
Public Health 2009; 40: 1284-92.
Mohr JF III. Update on the efficacy and tolerability
of meropenem in the treatment of serious bacterial
infections. Clin Infect Dis 2008; 47 (Suppl 1): S41-51.
Baughman RP. The use of carbapenems in the
treatment of serious infections. J Intensive Care
Med 2009; 24: 230-41.
Baldwin CM, Lyseng-Williamson KA, Keam SJ.
Meropenem: a review of its use in the treatment of
serious bacterial infections. Drugs 2008; 68: 803-38.
Silva E, Diaz JA, Arias MJ, Hernandez AP, de la Torre
A. Comparative in vitro study of the antimicrobial
activities of different commercial antibiotic
products for intravenous administration. BMC
Clin Pharmacol 2010; 10: 3.
Leelarasamee A, Rongrungruang Y, Trakulsomboon
S, Pongpech P, Thanawattanawanich P, Jithavech
P. Bioequivalence, antibacterial activity and
therapeutic outcome of a generic meropenem
(Mapenem). J Med Assoc Thai 2008; 91: 980-8.
Berman SJ, Fogarty CM, Fabian T, Melnick D,
Lesky W. Meropenem monotherapy for the
Potential conflicts of interest
None.
References
1. Kallen AJ, Hidron AI, Patel J, Srinivasan A.
Multidrug resistance among gram-negative
pathogens that caused healthcare-associated
infections reported to the National Healthcare
176
2.
3.
4.
5.
6.
7.
8.
9.
13 (6.8)
4 (2.1)
1 (0.5)
1 (0.5)
7 (3.7)
0
3 (1.6)
2 (1.1)
0
1 (0.5)
0.097
0.579
J Med Assoc Thai Vol. 94 No. 2 2011
10.
11.
12.
13.
treatment of hospital-acquired pneumonia: results
of a multicenter trial. J Chemother 2004; 16: 362-71.
Alvarez Lerma F. Efficacy of meropenem as
monotherapy in the treatment of ventilatorassociated pneumonia. J Chemother 2001; 13: 70-81.
Bartoloni A, Strohmeyer M, Corti G, Buonomini
MI, Franchino L, Romanelli G, et al. Multicenter
randomized trial comparing meropenem (1.5 g daily)
and imipenem/cilastatin (2 g daily) in the hospital
treatment of community-acquired pneumonia.
Drugs Exp Clin Res 1999; 25: 243-52.
Punpanich W, Tantichattanon W, Wongwatcharapaiboon S, Treeratweeraphong V.
In vitro susceptibility pattern of cephalosporinresistant Gram-negative bacteria. J Med Assoc
Thai 2008; 91 (Suppl 3): S21-7.
Thapa B, Tribuddharat C, Srifuengfung S,
Dhiraputra C. High prevalence of bla(OXA)-23 in
oligoclonal carbapenem-resistant Acinetobacter
baumannii from Siriraj Hospital, Mahidol
J Med Assoc Thai Vol. 94 No. 2 2011
University, Bangkok, Thailand. Southeast Asian J
Trop Med Public Health 2010; 41: 625-35.
14. Pongpech P, Amornnopparattanakul S,
Panapakdee S, Fungwithaya S, Nannha P,
Dhiraputra C, et al. Antibacterial activity
of carbapenem-based combinations againts
multidrug-resistant Acinetobacter baumannii. J
Med Assoc Thai 2010; 93: 161-71.
15. Kiratisin P, Apisarnthanarak A, Kaewdaeng S.
Synergistic activities between carbapenems and
other antimicrobial agents against Acinetobacter
baumannii including multidrug-resistant and
extensively drug-resistant isolates. Int J
Antimicrob Agents 2010; 36: 243-6.
16. Rongrungruang Y, Rittayamai N, Sangswangchot
P, Koomanachai P, Rattanaumpawan P,
Chinswangwatanakul V, et al. A prospective
open-label study on effectiveness and safety of a
generic meropenem. J Infect Dis Antimicrob Agents
2010; 27: 11-22.
177
ประสิทธิผลของยาสามัญเมโรพีเนมเปรียบเทียบกับยาต้นแบบในการรักษาการติดเชื้อรุนแรง:
การศึกษาสหสถาบัน
สมบูรณ์ ตันสุภสวัสดิกุล, ทรงชัย สิมะโรจน์, สมชาย จันทโรธร, นนทกานต์ นันทจิต, กมลวรรณ จุติวรกุล,
วรางคณา มัน่ สกุล, ขนิษฐา ยอมเต็ม, ฐิตริ ตั น์ ตัง้ ก่อสกุล, ศุภฤษณ์ วรรณสุนทรไชย
ภูมหิ ลัง: ยาปฏิชวี นะเมโรพีเนม มีบทบาทสำคัญในการรักษาโรคติดเชือ้ รุนแรงซึง่ ในปัจจุบนั มียาสามัญใช้ในประเทศไทย
แต่ยงั ขาดข้อมูลเกีย่ วกับประสิทธิผลและความปลอดภัยในการใช้เปรียบเทียบกับยาต้นแบบ การศึกษานีม้ วี ตั ถุประสงค์
เพื่อศึกษาประสิทธิผลและความปลอดภัยในการใช้ยาสามัญเมโรพีเนมในการรักษาผู้ป่วยโรคติดเชื้อรุนแรง
วัสดุและวิธีการ: รูปแบบการศึกษาที่ใช้ คือ การศึกษาแบบวิเคราะห์ข้อมูลย้อนหลังผู้ป่วยที่ได้รับการรักษา
ด้วยยาต้นแบบ หรือยาสามัญเมโรพีเนมใน 9 โรงพยาบาล ทำการประเมินผลการตอบสนองทางคลินกิ ณ วันที่ 3, 7,
14 ภายหลังการใช้ยาทั้ง 2 กลุ่ม และใช้ค่าทางสถิติ Kaplan-Meier ในการวิเคราะห์ข้อมูล
ผลการศึกษา: ผูป้ ว่ ยในการศึกษาทัง้ หมด 397 ราย ค่าอายุเฉลีย่ 66.4 ปี ผูป้ ว่ ยชายคิดเป็น 57.4% แบ่งเป็นกลุม่ ทีไ่ ด้รบั
ยาสามัญ 207 ราย (52.1%) และยาต้นแบบ 190 ราย (47.9%) ซึง่ อายุ เพศ โรคประจำตัว น้ำหนัก ของผูป้ ว่ ยทัง้ สองกลุม่
ไม่แตกต่างกัน ผูป้ ว่ ยส่วนใหญ่เป็นการติดเชือ้ ทางเดินหายใจ (48.6%) และกระแสโลหิต (29.5%) เชือ้ ก่อโรคส่วนใหญ่
ได้แก่ Pseudomonas aeruginosa, Acinetobacter baumannii และ (ESBL)-producing Escherichia coli
ตำแหน่งที่ติดเชื้อ เชื้อที่เป็นสาเหตุ ขนาดยาและระยะเวลาการได้รับยาของทั้งสองกลุ่มไม่แตกต่างกัน ผลการรักษา
ผู้ป่วย หายเป็นปกติ มีอาการดีขึ้น มีอาการคงที่ มีอาการแย่ลง ตายจากการติดเชื้อ และตายจากสาเหตุอื่น ๆ ณ
วันที่ 3, 7 และ 14 ไม่มีความแตกต่างกันทางนัยสำคัญทางสถิติ (p > 0.05) จากการวิเคราะห์ด้วย Kaplan-Meier
พบว่ า ผู ้ ป ่ ว ยที ่ ไ ด้ ร ั บ ยาสามั ญ มี ค วามน่ า จะเป็ น ของการรอดชี ว ิ ต สู ง กว่ า เล็ ก น้ อ ย แต่ ไ ม่ ม ี ค วามแตกต่ า งกั น
ทางนัยสำคัญทางสถิติ (log-rank test, p = 0.12) ยาทัง้ 2 กลุม่ มีความปลอดภัยและมีผปู้ ว่ ยน้อยกว่า 2% ทีต่ อ้ ง
หยุดยาจากอาการข้างเคียง
สรุป: ยาสามัญเมโรพีเนม (Mapenem) มีประสิทธิผลในการรักษาโรคติดเชื้อรุนแรงไม่แตกต่างจากยาต้นแบบ ยาทั้ง
2 สูตร มีความปลอดภัยในการใช้และอาการข้างเคียงที่ส่งผลให้ต้องหยุดยาพบน้อย
178
J Med Assoc Thai Vol. 94 No. 2 2011